Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride supplies electrolytes to maintain osmotic balance and fluid distribution.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replacement therapy,Treatment of dehydration,Maintenance of hydration and electrolyte balance,Provision of caloric support in parenteral nutrition
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion, rate depends on clinical condition; typical maintenance: 100-200 m L/hour for adults.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Glucose: ~1.5-2 hours (metabolic clearance); Sodium: biological half-life ~2-3 weeks (exchangeable pool); Chloride: ~12-24 hours (renal adaptation). Clinical context: Dextrose 2.5% provides ~85 kcal/L as glucose, rapidly cleared, while sodium and chloride are regulated by renal function and hormonal control.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis to pyruvate, entering the Krebs cycle for energy production; regulated by insulin and other hormones. Sodium chloride is not metabolized; it dissociates into Na+ and Cl- ions and is excreted primarily by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: Glucose is completely reabsorbed or metabolized; negligible excretion. Sodium and chloride are primarily excreted renally, with >90% reabsorption under normal conditions; excess is excreted in urine. Water follows solute excretion.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Glucose: <5% bound (non-specifically to albumin); Sodium and chloride: negligible (<1% bound).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: ~0.2 L/kg (intracellular distribution); Sodium: ~0.2-0.3 L/kg (extracellular fluid); Chloride: ~0.2-0.3 L/kg (extracellular fluid). Values represent distribution into total body water.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
IV: 100% bioavailability for all components. Not administered via other routes.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Anuria: contraindicated; severe impairment (e GFR <30 m L/min): use with caution and monitor fluid balance.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No dose adjustment recommended based on Child-Pugh score; monitor for fluid overload in cirrhosis.
No dosage adjustment required for hepatic impairment.
Weight-based: 4-8 mg/kg/min dextrose as continuous infusion; adjust rate based on serum glucose and electrolytes.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Use with caution due to decreased renal function; reduce infusion rate and monitor for hyperglycemia and fluid overload.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn or corn products (dextrose derived from corn). Solutions containing sodium chloride should be used with caution in patients with congestive heart failure, severe renal insufficiency, or conditions involving sodium retention.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Use with caution in patients with hyperglycemia, diabetes mellitus, renal impairment, congestive heart failure, or conditions predisposing to fluid overload. Monitor serum glucose, electrolytes, and fluid balance. Avoid extravasation; may cause tissue necrosis.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia with severe dehydration,Intracranial or intraspinal hemorrhage,Known hypersensitivity to corn or corn products,Severe electrolyte disturbances,Anuria or severe renal impairment with oliguria
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No known food interactions. However, dietary sodium and glucose intake may need adjustment based on patient's condition.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
No known teratogenic risk in any trimester at physiologic concentrations. Dextrose and sodium chloride are essential nutrients and electrolytes; no human or animal studies indicate teratogenicity. However, hyperglycemia from excessive dextrose may cause fetal macrosomia, neonatal hypoglycemia, or other diabetic fetopathy if maternal glucose is poorly controlled. Use caution in gestational diabetes.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Compatible with breastfeeding. Dextrose and electrolytes are normal milk constituents; no adverse effects expected. M/P ratio not applicable/unknown as these are endogenous substances.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No dose adjustment required under normal circumstances. Pregnancy increases plasma volume and glomerular filtration rate, but this does not necessitate dose change for isotonic/dextrose solutions as they are administered to maintain homeostasis. Monitor for fluid overload in preeclampsia or renal impairment. In gestational diabetes, dextrose infusion rate may need reduction and blood glucose monitoring.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This solution provides 85 m Eq/L sodium and 77 m Eq/L chloride. It is isotonic (308 m Osm/L) and suitable for maintenance fluids in euvolemic patients. Monitor for hypernatremia in renal impairment. Use with caution in heart failure due to sodium load. Do not administer simultaneously with blood products via same line due to risk of hemolysis.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution contains dextrose (sugar) and salt, which may affect blood glucose and blood pressure.,Report any shortness of breath, swelling, or rapid weight gain as these may indicate fluid overload.,If diabetic, monitor blood glucose more frequently during infusion.,Notify your healthcare provider if you have a history of kidney disease or heart failure.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides calories and serves as a source of glucose for cellular metabolism. Sodium chloride supplies electrolytes to maintain osmotic balance and fluid distribution.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion, rate depends on clinical condition; typical maintenance: 100-200 m L/hour for adults.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk in any trimester at physiologic concentrations. Dextrose and sodium chloride are essential nutrients and electrolytes; no human or animal studies indicate. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.